The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
Open accessAbstract
PURPOSE: Treatment options are limited for patients with recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 70% in patients with distant metastases. Here, we present the first interim analysis of the R/M cSCC cohort from the 2-cohort—locally advanced and R/M—phase II KEYNOTE-629 study. PATIENTS AND METHODS: Patients with R/M cSCC not amenable to surgery or radiation received pembrolizumab 200 mg every 3 weeks. The primary end point was objective response rate per RECIST v1.1. Secondary end points were duration of response, disease control rate, progression-free survival, overall survival, and safety. RESULTS: At data cutoff (April 8, 2019), median follow-up of 105 enrolled patients in the R/M cohort was 11.4 months (range, 0.4 to 16.3 months). Objective response rate was 34.3% (95% CI, 25.3% to 44.2%; 4 complete responses, 32 partial responses), and disease control rate was 52.4% (95% CI, 42.4% to 62.2%). Median duration of response was not reached (range, 2.7 to 13.1+ months; ‘+’ refers to ongoing response at data cutoff). Median progression-free survival was 6.9 months (95% CI, 3.1 months to 8.5 months). Median overall survival was not reached (95% CI, 10.7 months to not reached). Treatment-related adverse events occurred in 66.7% of patients (n = 70), the most common of which were pruritus (n = 15; 14.3%), asthenia (n = 14; 13.3%), and fatigue (n = 13; 12.4%). Grade 3 to 5 treatment-related adverse events occurred in 5.7% (n = 6) of patients. One patient died of treatment-related cranial nerve neuropathy. CONCLUSION: Pembrolizumab demonstrated effective antitumor activity; clinically meaningful, durable responses; and acceptable safety in primarily elderly patients with R/M cSCC, supporting its use in clinical practice. Pembrolizumab adverse events in this study were consistent with its established safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012
Rogers, H. W., Weinstock, M. A., Feldman, S. R., & Coldiron, B. M. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1187 · Cited by 1,815
Cohen, E. E. W., Soulières, D., Le Tourneau, C., Dinis, J., Licitra, L., Ahn, M.-J., Soria, A., Machiels, J.-P., Mach, N., Mehra, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,709
Self-citationPD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805131 · Cited by 1,411
Self-citationPD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Madan, V., Lear, J. T., & Szeimies, R.-M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61196-x · Cited by 884
Bauml, J., Seiwert, T. Y., Pfister, D. G., Worden, F., Liu, S. V., Gilbert, J., Saba, N. F., Weiss, J., Wirth, L., Sukari, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1524 · Cited by 663
Mutational landscape of aggressive cutaneous squamous cell carcinoma
Pickering, C. R., Zhou, J. H., Lee, J. J., Drummond, J. A., Peng, S. A., Saade, R. E., Tsai, K. Y., Curry, J. L., Tetzlaff, M. T., Lai, S. Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1768 · Cited by 612
Schmults, C. D., Karia, P. S., Carter, J. B., Han, J., & Qureshi, A. A. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.2139 · Cited by 571
Thompson, A. K., Kelley, B. F., Prokop, L. J., Murad, M. H., & Baum, C. L. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.4994 · Cited by 521
Cited by
Zeng, Q., Yang, J., Ji, J., Wang, P., Zhang, L., Yan, G., Wu, Y., Chen, Q., Liu, J., Zhang, G., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2061396 · Cited by 54
Fang, S., Wu, Y., Zhang, H., Zeng, Q., Wang, P., Zhang, L., Yan, G., Zhang, G., & Wang, X. (2022) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2022.102907 · Cited by 10
Metadata
- Authors
- Grob, J.-J., Gonzalez, R., Basset-Seguin, N., Vornicova, O., Schachter, J., Joshi, A., Meyer, N., Grange, F., Piulats, J. M., Bauman, J. R., Zhang, P., Gumuscu, B., Swaby, R. F., & Hughes, B. G. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-09-01
- Volume
- 38
- Issue
- 25
- Pages
- 2916-2925
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3043252982
- Cited by
- 301
- References
- 23
- FWCI
- 24.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). https://app.cochat.ai/papers/10.1200/jco.19.03054
- The paper
- Grob, J.-J., Gonzalez, R., Basset-Seguin, N., Vornicova, O., Schachter, J., Joshi, A., Meyer, N., Grange, F., Piulats, J. M., Bauman, J. R., Zhang, P., Gumuscu, B., Swaby, R. F., & Hughes, B. G. M. (2020). Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.03054
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.